Advertisement
Screener

Edgewise Therapeutics, Inc. (EWTX) Graph

EWTX Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $47.55M; Operating expenses $61.94M; Net income -$57.33M.
  • 2026-03-31: Research and development $42.65M; Operating expenses $54.12M; Net income -$49.01M.
  • 2025-12-31: Research and development $43.59M*; Operating expenses $55.98M*; Net income $117.41M*.
  • 2025-09-30: Research and development $37.48M; Operating expenses $46.86M; Net income -$40.67M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$47.55M$61.94M-$57.33M
2026-03-31$42.65M$54.12M-$49.01M
2025-12-31$43.59M*$55.98M*$117.41M*
2025-09-30$37.48M$46.86M-$40.67M
2025-06-30$33.56M$42.61M-$36.12M
2025-03-31$36.76M$45.96M-$40.80M
2024-09-30$32.22M$40.43M-$34.13M
2024-06-30$30.68M$38.11M-$31.50M
2024-03-31$27.69M$34.75M-$28.52M
2023-09-30$23.79M$29.45M-$25.71M
2023-06-30$19.56M$25.34M-$21.47M
2023-03-31$19.88M$25.70M-$22.84M
2022-09-30$13.89M$18.26M-$17.50M
2022-06-30$12.40M$16.49M-$16.07M
2022-03-31$11.12M$14.83M-$14.66M
2021-09-30$9.88M$13.08M-$12.95M
2021-06-30$7.86M$10.46M-$10.35M
2021-03-31$5.36M$6.86M-$6.82M
2020-09-30$3.24M$3.64M-$3.64M
2020-06-30$3.64M$3.96M-$3.95M
2020-03-31$2.97M$3.25M-$3.19M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$90.20M$116.06M-$106.34M
2025-06-30$70.31M$88.57M-$76.91M
2024-06-30$58.37M$72.86M-$60.02M
2023-06-30$39.44M$51.04M-$44.31M
2022-06-30$23.53M$31.32M-$30.73M
2021-06-30$13.22M$17.32M-$17.17M
2020-06-30$6.61M$7.21M-$7.14M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesNet income
2025-09-30$107.80M$135.43M-$117.58M
2024-09-30$90.60M$113.29M-$94.15M
2023-09-30$63.22M$80.50M-$70.02M
2022-09-30$37.42M$49.58M-$48.23M
2021-09-30$23.10M$30.39M-$30.12M
2020-09-30$9.84M$10.85M-$10.78M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$151.39M$191.41M$4.00K-$167.79K
2024-12-31$126.97M$158.83M$3.00K-$133.81K
2023-12-31$90.91M$114.36M$4.00K-$100.16K
2022-12-31$54.03M$71.66M$0.00-$67.64M
2021-12-31$32.19M$43.22M$0.00-$42.81M
2020-12-31$14.98M$17.19M(m)-$17.12M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51
Indivior Pharmaceuticals, Inc. (INDV)$4.250B14.09
Tango Therapeutics, Inc. (TNGX)United States$4.154B-42.53
Veradermics, Inc (MANE)United States$4.839B
AbCellera Biologics Inc. (ABCL)$3.879B-14.59
Erasca, Inc. (ERAS)United States$5.073B-19.96
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27